News | September 12, 2014

Mevion Medical Systems Introduces Hyperscan for Mevion S250 Platform

 Mevion_HYPERSCAN Proton Therapy
 Mevion_HYPERSCAN Proton Therapy

September 12, 2014 — Mevion Medical Systems introduced Hyperscan for the Mevion S250 modular single-room proton therapy system. Benefiting from direct and efficient proton beam generation, Hyperscan’s patented technology allows radiation to be precisely delivered using a sharp beam of radiation, with the tumor being volumetrically scanned in a matter of seconds. Current pencil beam delivery systems are known to be sensitive to motion, which can result in higher treatment uncertainties. Hyperscan’s fast beam delivery is much less sensitive to patient and tumor motions, thus delivering a more robust treatment.

“Hyperscan enables treatment with fine precision at tremendous speed and with uncompromised beam quality,” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems. “This new technological advance will help providers deliver the best possible cancer care to the patients who need it most.”

Hyperscan is debuting at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO), being held Sept. 14-16 in San Francisco. It is built on the Mevion S250 proton therapy platform that has been operating clinically since December 2013. The Hyperscan system features rapid volumetric and layer rescanning, a streamlined image-based clinical workflow, sub-millimeter position tracking and beam gating connectivity.

Simultaneously, Mevion is announcing it has reached an agreement with a financial services provider to offer financing to customers interested in purchasing the Mevion S250. This will provide Mevion’s customers with an alternative to traditional financing structures, should they desire it.

“The introduction of Hyperscan technology and the availability of alternative financing is a demonstration of Mevion’s continued commitment to improving the worldwide availability and clinical use of proton therapy,” said Jachinowski. “Mevion is dedicated to removing the obstacles of size, complexity and cost that exist with conventional proton therapy systems and making proton therapy as accessible as possible to the cancer patients who need it.”

The U.S. Food and Drug Administration (FDA) has not cleared Hyperscan for clinical use.

For more information: www.mevion.com

Related Content

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

News | Radiation Oncology | July 21, 2021
July 23, 2021 — Mevion Medical Systems announced that it has delivered the 15-ton compact accelerator to...
NeuroLogica joins forces with Massachusetts General Hospital to pilot OmniTom Elite with Photon Counting Detector (PCD) technology at patient point-of-care

NeuroLogica joins forces with Massachusetts General Hospital to pilot OmniTom Elite with Photon Counting Detector (PCD) technology at patient point-of-care. (Photo: Business Wire)

News | Computed Tomography (CT) | July 13, 2021
July 13, 2021 — NeuroLogica Corp.
 Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) and began treating patients on May 11 with the MEVION S250i Proton Therapy System.

The teams from HCI, U of U and Mevion gather to celebrate the center’s grand opening. Group from left to right: Bill Salter, Ph.D., Senior Director of Radiation Oncology, HCI and Professor and Chief of the Division of Medical Physics, U of U -- Robyn Walker, Sr. Director, Customer Success and Service Operations, Mevion -- James Cooley, Ph.D., Director of Advanced Development, Mevion -- Dennis Shrieve, M.D., Ph.D., Chair in Cancer Research, HCI and Chair of Department of Radiation Oncology, U of U -- Tina Yu, Ph.D., CEO, Mevion -- Michael Good, M.D., Interim President, U of U and Sr. VP for Health Sciences, U of U Health -- Ying Hitchcock, M.D., Professor and Medical Director, Department of Radiation Oncology, U of U. (Photo: Business Wire)

News | Proton Therapy | June 24, 2021
June 24, 2021 — Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin
RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.
News | Brachytherapy Systems | December 29, 2020
December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment plannin
C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the U.S.
News | Proton Therapy | December 28, 2020
December 28, 2020 — C-RAD offers a specific version of its Catalyst System for use in...
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Be sure to register for the American Society for Radiation Oncology's (ASTRO) 62nd Annual Meeting, to be held October 24-28, 2020, via an interactive virtual platform. The meeting, Global Oncology: Radiation Therapy in a Changing World, will feature reports from the latest clinical trials; panels on global oncology, health disparities and the novel coronavirus; and an immersive attendee experience in a virtual convention center.
News | ASTRO | October 23, 2020
October 23, 2020 — Be sure to ...
IBA showcases how its Proteus solutions and its network of clinical and industrial partners are shaping the future of proton therapy
News | Proton Therapy | October 23, 2020
October 23, 2020 — IBA, a leading provider of proton thera...
RaySearch Laboratories AB will demo its latest advances in oncology software at the American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting
News | Radiation Oncology | October 23, 2020
October 23, 2020 — RaySearch will present recent and upcoming enhancements, as well as new functionality, in...
Mevion Medical Systems announced that it has shipped the accelerator module for the Mevion S250i Proton Therapy System to Kunshan, China. The 15-ton compact accelerator, the heart of the proton therapy system, is the smallest of its kind and will be the first in China.

Mevion's compact accelerator module is lifted and placed on a truck for the first leg of its journey to China. (Photo: Business Wire)

News | Proton Therapy | October 16, 2020
October 16, 2020 — Mevion Medical Systems announced that it has shipped the accelerator module for the...